Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem

BACKGROUND: Daridorexant, a dual orexin receptor antagonist approved in early 2022, reduces wake after sleep onset without reducing the number of awakenings in patients with insomnia. The objective of this post hoc analysis was to explore the effect of daridorexant on the number, duration, and distr...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Marco, Tobias, Scammell, Thomas E., Meinel, Michael, Seboek Kinter, Dalma, Datta, Alexandre N., Zammit, Gary, Dauvilliers, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374812/
https://www.ncbi.nlm.nih.gov/pubmed/37477771
http://dx.doi.org/10.1007/s40263-023-01020-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374812/
https://www.ncbi.nlm.nih.gov/pubmed/37477771
http://dx.doi.org/10.1007/s40263-023-01020-9

Ejemplares similares